The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Replacement Astrazeneca Plc

27 May 2014 13:27

RNS Number : 1316I
Morgan Stanley Capital Services LLC
27 May 2014
 



AMENDMENT

 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

19 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 ADRS

 PURCHASES

 47,427.00 (Traded in ADR form)

 72.6900 USD

 70.1000 USD

 ADRS

 SALES

 692,714.00 (Traded in ADR form)

 72.8300 USD

 69.8300 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 USD 0.25 ORDINARY

 CFD

 LONG

 990

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 5,922

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 6,781

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 94,002

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 23,290

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 26,732

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 135,367

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 29,457

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 5,419

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 1,418

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 388

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 8,776

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 25,197

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 6,897

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 6,389

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 68,018

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 4,957

 41.7367 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 75,000

 41.7500 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 45,822

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 210,572

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 9,939

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 10,728

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 39,196

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 13,652

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 602

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 2,205

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 146,224

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 41,583

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 36,230

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 10,547

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 9,212

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 1,540

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 7,712

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 8,430

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 105,806

 41.8834 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 2,400

 41.9832 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 300

 41.9832 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 3,206

 41.9832 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 13,780

 42.1767 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 5,500

 42.3364 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 500

 42.3364 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 4,000

 42.3364 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 230,827

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 65,642

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 57,191

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 167,023

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 13,306

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 12,172

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 2,431

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 14,542

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 16,650

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 332,400

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 72,334

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 21,550

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 15,690

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 16,935

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 61,874

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 952

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 3,481

 42.4686 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 1,071

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 293

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 19,038

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 5,211

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 6,631

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 102,276

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 4,828

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 22,257

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 5,123

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 4,474

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 748

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 3,745

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 4,094

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 51,392

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 17,597

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 20,198

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 71,024

 42.5284 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 2,000

 42.5935 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 300

 42.7296 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 2,700

 42.7296 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 2,000

 42.7296 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 39,000

 42.8764 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 220

 42.9314 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 230

 41.7038 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 600

 41.7038 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 658

 41.7038 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 16,337

 41.7038 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 4,997

 41.7038 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 518

 41.7038 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 4,370

 41.7038 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 14,000

 41.7405 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 667

 41.7868 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 255

 41.7868 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 4,855

 41.7868 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 576

 41.7868 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 5,551

 41.7868 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 18,151

 41.7868 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 731

 41.7868 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 23,512

 42.5072 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 19,775

 42.5072 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 6,452

 42.5072 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 1,733

 42.5072 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 1,515

 42.5072 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 906

 42.5072 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 611

 42.5072 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 1,000

 42.5230 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 4,000

 43.0794 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 500

 43.0794 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 5,500

 43.0794 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 300

 43.2597 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 2,000

 43.2597 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 2,700

 43.2597 GBP

 ADRS

 CFD

LONG

 1,600.00 (Traded in ADR form)

 70.7400 USD

 ADRS

 CFD

LONG

 3,390.00 (Traded in ADR form)

 71.1535 USD

 ADRS

 CFD

LONG

 2,600.00 (Traded in ADR form)

 71.4000 USD

 ADRS

 CFD

LONG

 9,500.00 (Traded in ADR form)

 71.8235 USD

 ADRS

 CFD

LONG

 148,400.00 (Traded in ADR form)

 71.9079 USD

 ADRS

 CFD

SHORT

 172.00 (Traded in ADR form)

 70.3625 USD

 ADRS

 CFD

SHORT

 228.00 (Traded in ADR form)

 70.3625 USD

 ADRS

 CFD

SHORT

 152.00 (Traded in ADR form)

 70.4914 USD

 ADRS

 CFD

SHORT

 115.00 (Traded in ADR form)

 70.4914 USD

 ADRS

 CFD

SHORT

 1,300.00 (Traded in ADR form)

 70.6962 USD

 ADRS

 CFD

SHORT

 5,100.00 (Traded in ADR form)

 71.0386 USD

 ADRS

 CFD

SHORT

 2,600.00 (Traded in ADR form)

 71.5728 USD

 ADRS

 CFD

SHORT

 20,700.00 (Traded in ADR form)

 71.7150 USD

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 ADRS

 PUT

SALE

 500.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 5.9000 USD

 ADRS

 PUT

SALE

 500.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 7.7000 USD

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

27 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERSEIFEWFLSEEI
Date   Source Headline
2nd May 20247:00 amRNSCalquence combination improved PFS in 1L MCL
1st May 20243:00 pmRNSTotal Voting Rights
29th Apr 20247:05 amRNSTruqap recommended for EU breast cancer approval
29th Apr 20247:00 amRNSEnhertu improved PFS in HER2-low and ultralow
25th Apr 20247:00 amRNS1st Quarter Results
11th Apr 20245:30 pmRNSResult of AGM
11th Apr 20247:00 amRNSAstraZeneca increases 2024 dividend by 7%
8th Apr 20247:00 amRNSEnhertu approved in US for HER2+ solid tumours
5th Apr 20247:00 amRNSImfinzi improved OS & PFS in limited-stage SCLC
2nd Apr 20243:00 pmRNSTotal Voting Rights
2nd Apr 20247:05 amRNSVoydeya approved in US
2nd Apr 20247:00 amRNSFDA accepts Dato-DXd BLA for breast cancer
25th Mar 20247:00 amRNSUltomiris approved in the US for NMOSD
19th Mar 20247:00 amRNSAstraZeneca to acquire Fusion
14th Mar 20247:00 amRNSAstraZeneca to acquire Amolyt
12th Mar 202411:00 amRNSDirector/PDMR Shareholding
7th Mar 202411:00 amRNSNotice of AGM
6th Mar 20243:05 pmRNSDirector/PDMR Shareholding
6th Mar 20243:00 pmRNSDirector/PDMR Shareholding
4th Mar 20247:00 amRNSEMA validates Dato-DXd MAAs for NSQ NSCLC and BC
1st Mar 20243:00 pmRNSTotal Voting Rights
26th Feb 20247:00 amRNSVoydeya recommended for EU approval
22nd Feb 20241:15 pmRNSAcquisition of Gracell completed
22nd Feb 202411:00 amRNSDirector/PDMR Shareholding
22nd Feb 20247:00 amRNSAstraZeneca prices a $5bn bond offering
21st Feb 20247:00 amRNSFiling of Form 20-F with SEC
20th Feb 202411:00 amRNSAnnual Financial Report
19th Feb 20243:00 pmRNSAstraZeneca completes acquisition of Icosavax
19th Feb 20247:10 amRNSTagrisso plus chemo approved in US for lung cancer
19th Feb 20247:05 amRNSFDA accepts Dato-DXd BLA for nonsquamous NSCLC
19th Feb 20247:00 amRNSTagrisso improved PFS in Stage III lung cancer
8th Feb 20247:00 amRNSFinal Results
1st Feb 20243:00 pmRNSTotal Voting Rights
2nd Jan 20243:00 pmRNSTotal Voting Rights
27th Dec 20237:00 amRNSAstraZeneca acquires Gracell
22nd Dec 20237:00 amRNSWainua (eplontersen) granted first US FDA approval
14th Dec 20233:00 pmRNSDirector/PDMR Shareholding
12th Dec 20237:05 amRNSAstraZeneca to acquire Icosavax
1st Dec 20233:05 pmRNSBlock listing Interim Review
1st Dec 20233:00 pmRNSTotal Voting Rights
1st Dec 20237:00 amRNSDiscontinuation of two CRYSTALIZE evidence trials
23rd Nov 20233:00 pmRNSDirector/PDMR Shareholding
17th Nov 20237:00 amRNSTruqap approved in US for HR+ breast cancer
14th Nov 20237:05 amRNSUpdate on PACIFIC-2 Phase III trial for Imfinzi
9th Nov 20233:00 pmRNSDirector Declaration
9th Nov 20237:10 amRNSImfinzi combination improves PFS in liver cancer
9th Nov 20237:05 amRNSAgreement with Eccogene for clinical stage GLP-1RA
9th Nov 20237:00 amRNS9M and Q3 2023 results
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSAstraZeneca cell & gene therapy deal w/ Cellectis

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.